- Home
- SSRM vs ORKA Comparison
SSRM vs ORKA Comparison
Compare SSRM & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSRM
- ORKA
- Stock Information
- Founded
- SSRM 1946
- ORKA 2004
- Country
- SSRM United States
- ORKA United States
- Employees
- SSRM N/A
- ORKA N/A
- Industry
- SSRM Precious Metals
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SSRM Industrials
- ORKA Health Care
- Exchange
- SSRM Nasdaq
- ORKA Nasdaq
- Market Cap
- SSRM 2.2B
- ORKA 354.2M
- IPO Year
- SSRM 1996
- ORKA N/A
- Fundamental
- Price
- SSRM $13.14
- ORKA $12.60
- Analyst Decision
- SSRM Hold
- ORKA Strong Buy
- Analyst Count
- SSRM 3
- ORKA 8
- Target Price
- SSRM $10.53
- ORKA $39.71
- AVG Volume (30 Days)
- SSRM 3.1M
- ORKA 341.3K
- Earning Date
- SSRM 07-30-2025
- ORKA 08-15-2025
- Dividend Yield
- SSRM N/A
- ORKA N/A
- EPS Growth
- SSRM N/A
- ORKA N/A
- EPS
- SSRM 0.42
- ORKA N/A
- Revenue
- SSRM $1,082,002,000.00
- ORKA N/A
- Revenue This Year
- SSRM $40.21
- ORKA N/A
- Revenue Next Year
- SSRM $19.05
- ORKA N/A
- P/E Ratio
- SSRM $31.52
- ORKA N/A
- Revenue Growth
- SSRM N/A
- ORKA N/A
- 52 Week Low
- SSRM $4.32
- ORKA $5.49
- 52 Week High
- SSRM $13.46
- ORKA $52.32
- Technical
- Relative Strength Index (RSI)
- SSRM 62.45
- ORKA N/A
- Support Level
- SSRM $12.04
- ORKA N/A
- Resistance Level
- SSRM $12.67
- ORKA N/A
- Average True Range (ATR)
- SSRM 0.48
- ORKA 0.00
- MACD
- SSRM -0.02
- ORKA 0.00
- Stochastic Oscillator
- SSRM 86.56
- ORKA 0.00
About SSRM SSR Mining Inc.
SSR Mining Inc is a minerals company focused on mining precious metals in the Americas. More than half of Silver Standard's revenue is attributable to the production of gold, with a key portion derived from silver production. The company owns and operates the Marigold mine in Nevada, United States; the Seabee Gold Operation in Saskatchewan, Canada; and the Puna mine in Argentina. The majority of gold production is derived from the Marigold mine, and Silver Standard's silver production is principally derived from the Puna mine.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.